AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 OCT 6 - (NewsRx.com & NewsRx.net) -- Anti-polysaccharide IgG antibodies are associated with the risk of invasive pneumococcal disease in Ugandan adults infected with HIV-1.
According to a study from Malawi, "We have investigated the association between the concentration of anti-polysaccharide pneumococcal capsule-specific (anti-PS) immunoglobulin G and the killing activity, in serum, in invasive pneumococcal disease (IPD) events and response to 23-valent polysaccharide vaccine in human immunodeficiency virus (HIV)-infected Ugandans. Case patients with IPD had lower concentrations of anti-PS IgG before and after vaccination and before the IPD event (p
"After vaccination, case patients were less likely than were control subjects to develop detectable serum killing activity against the two serotypes tested - for 19F, this activity was detected in 16% of case patients versus 37% of control subjects (p=0.08); for 23F, it was detected in 11% of case patients versus 40% of control subjects (p=0.02)," reported Neil French at the Liverpool School of Tropical Medicine in England and collaborators in England, Finland, and Malawi. "Thus, absolute ...
Source: HighBeam Research, Anti-polysaccharide IgG linked to pneumococcal disease risk in HIV-1.